C2i Genomics is a company in the Health Care industry, founded in 2019 and headquartered in the United States. The company recently received a $100.00M Series B investment on April 15, 2021, with participation from notable investors including LionBird, Casdin Capital, iGlobe Partners, Driehaus Capital Management, Section 32, The Mark Foundation for Cancer Research, Duquesne Family Office, Alexandria Real Estate Equities, Gordon Asset Management, and NFX Bio. C2i Genomics' mission is to transform cancer care through the application of AI and genomics, which led to its acquisition by Veracyte. The merger with Veracyte opens up new opportunities and potential for growth in the evolving field of genomic diagnostics and personalized medicine.
C2i Genomics
C2i Genomics is now part of Veracyte. We encourage you to follow Veracyte on LinkedIn.
Founded 2019
New York, United States
26 employees
Series B
Total: $112.00M
Health Care, Health and Wellness
New York, United States
26 employees
Series B
Total: $112.00M
Health Care, Health and Wellness
General Information
Company Name
C2i Genomics
Founded Year
2019
Location
New York, United States
New York, United States
Employees
26
Industries
Health Care, Health and Wellness
Funding Stage
Series B
BounceWatch is an independent company data service, not affiliated with C2i Genomics. To contact C2i Genomics, visit c2i-genomics.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does C2i Genomics compare?
A PDF of C2i Genomics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting C2i Genomics soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Health Care
About C2i Genomics
Business keywords: C2i Genomics, Veracyte, Genomics, Medical Diagnostics, Cancer Diagnosis, Acquisition, LinkedIn, Health Technology, Mergers and Acquisitions
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series B | $100.00M | 10 |
|
15 Apr 2021 |
| Series A | $12.00M | - |
|
09 Jun 2020 |
C2i Genomics Alternatives & Competitors
View All Alternatives
C2i Genomics vs
Gabbi
United States
Making late stage Breast Cancer obsolete
Seed
23 employees
Health Care, Health and Wellness
C2i Genomics vs
Ruby Consulting Group
United States
Helping health companies with radical transformations of their marketing, branding and commercial st...
1 employees
Advertising, Biotechnology
C2i Genomics vs
DeepX Health
United States
We improve patient care and save lives.
11 employees
Health Care, Health and Wellness
FAQ About C2i Genomics
C2i Genomics is now part of Veracyte. We encourage you to follow Veracyte on LinkedIn.
C2i Genomics was founded in 2019.
C2i Genomics is headquartered in New York, United States.
C2i Genomics operates in Health Care and Health and Wellness. Its work centres on C2i Genomics, Veracyte, Genomics and Medical Diagnostics.
C2i Genomics has approximately 26 employees.
C2i Genomics has completed 2 funding rounds, raising a total of $112.00M. The latest funding stage is Series B.
Top alternatives and competitors to C2i Genomics include Gabbi, Ruby Consulting Group, DeepX Health , Prenetics, Patheous Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
C2i Genomics and Gabbi are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for C2i Genomics, https://bouncewatch.com/company/c2i-genomics, updated 30 December 2024. When citing, please name BounceWatch and link this page.
